Life Sciences
Top stories summarized by our editors
2/20/2018

An international team of researchers created a power source for implantable medical devices using the electric eel's shock-producing biochemical system as inspiration. The device, which consists of stacks of hydrogels that have different salinity levels and are serially wired using 3D-printing technology, can release up to 110 volts of electrical current when folded, the scientists reported in the journal Nature.

2/20/2018

An upsized follow-on funding brought in $300 million for Amicus Therapeutics. Amicus' new-drug application for migalastat, indicated for patients 16 years of age or older with Fabry's disease who have amenable mutations, received priority review status by the FDA.

Full Story:
BioCentury
2/20/2018

Food Standards Australia New Zealand released a consultation paper encouraging views on how it will regulate food products derived from biotechnology. "The review is being conducted to ensure that a broad range of issues has been considered before any decision is made to consider varying the Code," said FSANZ CEO Mark Booth.

Full Story:
FoodNavigator-Asia
2/20/2018

The PT Jakarta Tank Terminal's total tank capacity for ethanol, biodiesel and gas will be expanded to more than 350,000 cbm, including an additional eight tanks with a capacity of 100.000 cbm. The expansion will enable compliance with Indonesia's Biofuel Blending Mandate regulations.

Full Story:
Biofuels Digest
2/20/2018

An Intention to Float has been published by Siemens as it prepares for an initial public offering of its medtech division, Siemens Healthineers, at the DAX stock exchange in Germany, which could take place as early as March. Siemens noted that it will retain a majority stake in the unit and will eventually provide support for the division.

More Summaries:
Siemens, Siemens Healthineers, DAX
2/20/2018

Omar Ishrak, chairman and CEO of Medtronic, discusses the company's venture into outcomes-based contracts, which he said help companies ensure fair payment when the value created with their products is realized. Ishrak sees chronic-disease management as a growth area for outcomes-based deals, and hopes that all the company's revenue will be tied to outcomes-based measurements.

More Summaries:
Medtronic, Omar Ishrak
2/20/2018

An initial public offering of 3.5 million shares of common stock has been closed by Motus GI, raising $17.5 million in gross proceeds. The company, which granted a 30-day option for the underwriters to buy 525,000 additional shares, intends to use the net proceeds as working capital, to commercialize its Pure-Vu colonoscopy device and to support research and development efforts.

Full Story:
Globes (Israel)
2/20/2018

A planned initial coin offering could bring in around $18.5 million for Cyprus-based NnBU, which is developing a blockchain-based medical device for providing healthy outcomes for caesarean-section newborns through torso massage and simulation of the positive stresses of natural childbirth. The company, which earned a patent for the neonatal birth unit after completion of the product's conceptual design, intends to use the proceeds to support product development and commercialization.

More Summaries:
ICO
2/20/2018

A business center will be built by California-based Quidel in Ireland to better position itself in providing services to customers in the international market -- a move that will create 75 jobs. The company hopes to hire people for finance, customer service, technical support, human resources, sales, marketing, legal and information technology roles in the facility over the next five years.

More Summaries:
Quidel
2/20/2018

Hologic saw a $701.1 million year-over-year revenue growth during the fiscal first quarter ending Dec. 30 of last year, driven by its molecular diagnostics, breast health and international businesses. Chairman, President and CEO Steve MacMillan said, "[T]ax reform is helping us increase our earnings guidance for the year, while simultaneously re-investing in the business to drive future growth."

Full Story:
Patch
More Summaries:
Steve MacMillan